COVID-19 convalescent plasma should only be given to clinical trial patients
If convalescent plasma is transfused in error it is a SHOT-reportable incident
A reminder that convalescent plasma should only be given to patients enrolled on the trials, and stocks should be kept separate to standard FFP (this information is provided on signing up to the REMAP-CAP and RECOVERY clinical trials)
If convalescent plasma in transfused in error in place of FFP it is a SHOT-reportable incident, because the wrong component was transfused.
Lucy Frith, Process Improvement Manager